Cachet Pharmaceutical Co., Ltd. (002462.SZ)
CNY 13.73
(-0.94%)
CNY 13.73
(-0.94%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 733.77 Million CNY | -40.62% |
| 2022 | 936.89 Million CNY | 12.77% |
| 2021 | 830.76 Million CNY | -30.48% |
| 2020 | 1.19 Billion CNY | 34.1% |
| 2019 | 891.1 Million CNY | 14.66% |
| 2018 | 777.16 Million CNY | 23.05% |
| 2017 | 631.58 Million CNY | 15.83% |
| 2016 | 545.28 Million CNY | 36.65% |
| 2015 | 399.05 Million CNY | -1.84% |
| 2014 | 406.54 Million CNY | 146.86% |
| 2013 | 164.68 Million CNY | 79.5% |
| 2012 | 91.74 Million CNY | 31.72% |
| 2011 | 69.65 Million CNY | 6.73% |
| 2010 | 65.26 Million CNY | 15.8% |
| 2009 | 56.35 Million CNY | 11.07% |
| 2008 | 50.74 Million CNY | -76.1% |
| 2007 | 212.31 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 150.51 Million CNY | 104.53% |
| 2024 Q3 | 149.69 Million CNY | -36.15% |
| 2024 Q2 | 234.45 Million CNY | 55.77% |
| 2023 Q3 | 171.13 Million CNY | -4.03% |
| 2023 Q4 | 73.58 Million CNY | -57.0% |
| 2023 Q1 | 133.31 Million CNY | 24.35% |
| 2023 FY | 556.36 Million CNY | -40.62% |
| 2023 Q2 | 178.31 Million CNY | 33.75% |
| 2022 FY | 936.89 Million CNY | 12.77% |
| 2022 Q1 | 307.26 Million CNY | 66.65% |
| 2022 Q4 | 107.21 Million CNY | -74.08% |
| 2022 Q3 | 413.62 Million CNY | 34.27% |
| 2022 Q2 | 308.05 Million CNY | 0.26% |
| 2021 Q3 | 211.05 Million CNY | -10.59% |
| 2021 FY | 830.76 Million CNY | -30.48% |
| 2021 Q2 | 236.04 Million CNY | 18.45% |
| 2021 Q1 | 199.28 Million CNY | -19.88% |
| 2021 Q4 | 184.38 Million CNY | -12.64% |
| 2020 Q2 | 198.65 Million CNY | 75.13% |
| 2020 Q4 | 248.74 Million CNY | -5.77% |
| 2020 FY | 1.19 Billion CNY | 34.1% |
| 2020 Q1 | 113.42 Million CNY | -43.66% |
| 2020 Q3 | 263.96 Million CNY | 32.88% |
| 2019 FY | 891.1 Million CNY | 14.66% |
| 2019 Q3 | 213.92 Million CNY | -17.76% |
| 2019 Q1 | 215.69 Million CNY | 25.55% |
| 2019 Q4 | 201.33 Million CNY | -5.89% |
| 2019 Q2 | 260.14 Million CNY | 20.61% |
| 2018 FY | 777.16 Million CNY | 23.05% |
| 2018 Q3 | 189.99 Million CNY | -15.84% |
| 2018 Q1 | 189.6 Million CNY | 17.76% |
| 2018 Q2 | 225.76 Million CNY | 19.07% |
| 2018 Q4 | 171.79 Million CNY | -9.58% |
| 2017 Q4 | 161 Million CNY | 10.29% |
| 2017 Q2 | 163.19 Million CNY | 1.11% |
| 2017 FY | 631.58 Million CNY | 15.83% |
| 2017 Q1 | 161.39 Million CNY | 13.44% |
| 2017 Q3 | 145.99 Million CNY | -10.54% |
| 2016 FY | 545.28 Million CNY | 36.65% |
| 2016 Q4 | 142.27 Million CNY | 4.28% |
| 2016 Q1 | 126.14 Million CNY | 22.84% |
| 2016 Q2 | 140.41 Million CNY | 11.31% |
| 2016 Q3 | 136.44 Million CNY | -2.83% |
| 2015 Q3 | 97 Million CNY | -14.37% |
| 2015 Q1 | 86.07 Million CNY | -5.27% |
| 2015 Q2 | 113.27 Million CNY | 31.6% |
| 2015 FY | 399.05 Million CNY | -1.84% |
| 2015 Q4 | 102.69 Million CNY | 5.87% |
| 2014 Q2 | 66.24 Million CNY | -62.87% |
| 2014 FY | 406.54 Million CNY | 146.86% |
| 2014 Q4 | 90.86 Million CNY | 27.93% |
| 2014 Q3 | 71.02 Million CNY | 7.22% |
| 2014 Q1 | 178.41 Million CNY | 168.79% |
| 2013 Q2 | 38.44 Million CNY | 54.57% |
| 2013 Q3 | 34.99 Million CNY | -8.98% |
| 2013 Q1 | 24.87 Million CNY | 78.71% |
| 2013 Q4 | 66.37 Million CNY | 89.69% |
| 2013 FY | 164.68 Million CNY | 79.5% |
| 2012 Q4 | 13.91 Million CNY | -41.29% |
| 2012 FY | 91.74 Million CNY | 31.72% |
| 2012 Q2 | 34.82 Million CNY | 80.45% |
| 2012 Q3 | 23.7 Million CNY | -31.93% |
| 2012 Q1 | 19.29 Million CNY | 91.32% |
| 2011 Q3 | 18.07 Million CNY | -37.11% |
| 2011 Q1 | 12.75 Million CNY | -24.0% |
| 2011 Q2 | 28.73 Million CNY | 125.25% |
| 2011 Q4 | 10.08 Million CNY | -44.19% |
| 2011 FY | 69.65 Million CNY | 6.73% |
| 2010 Q2 | 25.96 Million CNY | 212.2% |
| 2010 Q4 | 16.78 Million CNY | 18.28% |
| 2010 Q3 | 14.19 Million CNY | -45.34% |
| 2010 FY | 65.26 Million CNY | 15.8% |
| 2010 Q1 | 8.31 Million CNY | -37.89% |
| 2009 Q3 | 22 Million CNY | 0.0% |
| 2009 Q4 | 13.39 Million CNY | -39.14% |
| 2009 FY | 56.35 Million CNY | 11.07% |
| 2008 FY | 50.74 Million CNY | -76.1% |
| 2007 FY | 212.31 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yixintang Pharmaceutical Group Co., Ltd. | 786.44 Million CNY | 6.697% |
| ZJAMP Group Co., Ltd. | 1.05 Billion CNY | 30.2% |
| Luyan Pharma Co.,Ltd. | 468.55 Million CNY | -56.603% |
| Ji Yao Holding Group Co., Ltd. | -346.79 Million CNY | 311.589% |